When the bivalent Vδ2hi-lo VHHs were linked to VHHs directed against a variety of TAA specific VHHs (i.e. EGFR, PSMA or CD1d, molecules that can be over-expressed by tumor cells (31, 32, 66)) alone or with an Fc or anti-albumin binding domain for half-life extension, enrichment and expansion were maintained at levels similar to those obtained with the N-BP pamidronate. The gene discussed is FOLH1; the disease is neoplasm.